PRODUCT INFORMATION

Remoxipride (hydrochloride)

Item No. 30971

CAS Registry No.: 73220-03-8
Formal Name: 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxy-benzamide, monohydrochloride
MF: $C_{16}H_{23}BrN_2O_3 \bullet HCl$
FW: 407.7
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Remoxipride (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the remoxipride (hydrochloride) in water. The solubility of remoxipride (hydrochloride) in water is approximately 100 nM. We do not recommend storing the aqueous solution for more than one day.

Description

Remoxipride is an atypical antipsychotic and dopamine D_2 receptor antagonist (K_i = 0.2 µM).[1] It is selective for the dopamine D_2 receptor over a panel of 33 receptors, neurotransmitter transporters, and ion channels at 10 µM but does inhibit the sigma (σ) receptor (K_i = 0.065 µM). Remoxipride (2-20 µmol/kg, i.p.) increases striatal 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in rats.[2] It inhibits apomorphine-induced stereotypy and hyperactivity in rats with ED_{50} values of 5.6 and 0.8 µmol/kg, respectively.[3] Formulations containing remoxipride have previously been used in the treatment of schizophrenia.

References

1. Leysen, J.E., Janssen, P.M.F., Schotte, A., *et al.* Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of $5HT_2$ receptors. *Psychopharmacology (Berl).* **112(1 Suppl.)**, S40-54 (1993).
2. Magnusson, O., Mohringe, B., Thorell, G., *et al.* Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration. *Pharmacol. Toxicol.* **60(5)**, 368-373 (1987).
3. Ogren, S.O., Hall, H., Kohler, C., *et al.* Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. *Eur. J. Pharmacol.* **102(3-4)**, 459-574 (1984).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM